See more : Kingworld Medicines Group Limited (1110.HK) Income Statement Analysis – Financial Results
Complete financial analysis of JETEMA, Co., Ltd. (216080.KQ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of JETEMA, Co., Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- Shantui Construction Machinery Co., Ltd. (000680.SZ) Income Statement Analysis – Financial Results
- PTT Exploration and Production Public Company Limited (PTTEP-R.BK) Income Statement Analysis – Financial Results
- Powered Brands (POW) Income Statement Analysis – Financial Results
- Acusensus Limited (ACE.AX) Income Statement Analysis – Financial Results
- iCatch Technology, Inc. (6695.TWO) Income Statement Analysis – Financial Results
JETEMA, Co., Ltd. (216080.KQ)
About JETEMA, Co., Ltd.
JETEMA, Co., Ltd., a bio venture company, engages in the research and development of medicines and medical devices. It offers botulinum toxins, fillers, anti-aging solutions, lifting threads for medical treatment, laser surgical instruments, and skin care hyaluronic acid masks. The company is headquartered in Wonju, South Korea.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 58.72B | 45.99B | 33.22B | 20.66B | 13.30B | 11.21B | 8.17B |
| Cost of Revenue | 30.42B | 25.53B | 19.08B | 12.66B | 7.95B | 6.16B | 5.63B |
| Gross Profit | 28.30B | 20.47B | 14.14B | 8.00B | 5.35B | 5.05B | 2.54B |
| Gross Profit Ratio | 48.19% | 44.50% | 42.58% | 38.72% | 40.21% | 45.02% | 31.05% |
| Research & Development | 10.22B | 5.17B | 3.40B | 4.63B | 7.39B | 3.51B | 1.62B |
| General & Administrative | 1.26B | 938.22M | 703.22M | 668.39M | 173.81M | 0.00 | 0.00 |
| Selling & Marketing | 5.80B | 4.76B | 2.44B | 3.46B | 3.90B | 0.00 | 0.00 |
| SG&A | 7.06B | 12.05B | 8.33B | 8.68B | 8.59B | 6.07B | 4.74B |
| Other Expenses | 8.38B | -313.65M | -132.70M | -278.24M | -96.48M | -10.68M | -184.13M |
| Operating Expenses | 25.66B | 17.54B | 11.87B | 13.59B | 16.08B | 9.60B | 6.54B |
| Cost & Expenses | 56.08B | 43.07B | 30.94B | 26.25B | 24.04B | 15.76B | 12.18B |
| Interest Income | 266.99M | 410.67M | 194.32M | 168.86M | 127.66M | 104.30M | 13.77M |
| Interest Expense | 12.88B | 9.58B | 3.68B | 616.73M | 1.98B | 2.45B | 1.29B |
| Depreciation & Amortization | 8.37B | 4.93B | 3.37B | 3.08B | 1.61B | 927.06M | 804.52M |
| EBITDA | 22.36B | 16.90B | 17.93B | -5.11B | -9.12B | -13.50B | -3.64B |
| EBITDA Ratio | 38.08% | 17.07% | 17.00% | -12.15% | -68.59% | -32.33% | -39.17% |
| Operating Income | 2.63B | 2.92B | 2.28B | -5.59B | -10.73B | -4.55B | -4.00B |
| Operating Income Ratio | 4.49% | 6.36% | 6.86% | -27.04% | -80.71% | -40.61% | -49.02% |
| Total Other Income/Expenses | -1.58B | -2.12B | 8.61B | -3.35B | -3.62B | -11.18B | -1.57B |
| Income Before Tax | 1.05B | 2.39B | 10.88B | -8.80B | -14.35B | -15.73B | -5.57B |
| Income Before Tax Ratio | 1.80% | 5.20% | 32.76% | -42.61% | -107.92% | -140.33% | -68.22% |
| Income Tax Expense | -12.55B | 429.32M | 4.00 | 391.70M | 370.88M | 24.28M | 9.29M |
| Net Income | 13.97B | 1.46B | 10.88B | -9.33B | -14.72B | -15.75B | -5.58B |
| Net Income Ratio | 23.79% | 3.16% | 32.76% | -45.15% | -110.71% | -140.54% | -68.33% |
| EPS | 783.21 | 81.77 | 615.85 | -540.96 | -906.79 | -921.38 | -326.59 |
| EPS Diluted | 720.07 | 80.93 | 605.62 | -540.96 | -906.79 | -921.38 | -326.59 |
| Weighted Avg Shares Out | 17.83M | 17.79M | 17.67M | 17.24M | 16.24M | 17.10M | 17.10M |
| Weighted Avg Shares Out (Dil) | 19.40M | 17.98M | 17.97M | 17.24M | 16.24M | 17.10M | 17.10M |
Source: https://incomestatements.info
Category: Stock Reports